Asacol

DRUG3 trials

Sponsors

Shire, Annette Langseder, Warner Chilcott

Conditions

HealthyUlcerative Colitis

Phase 1

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

CompletedNCT00751699

Warner ChilcottHealthy

Start: 2007-03-31End: 2007-04-30Updated: 2013-04-17

Phase 3

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

CompletedNCT00151892

ShireUlcerative Colitis

Start: 2005-04-08End: 2009-09-07Updated: 2021-06-14

Unknown Phase

Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients

TerminatedNCT00349388

Annette LangsederUlcerative Colitis

Start: 2006-07-31End: 2011-01-31Updated: 2019-01-29

Related Papers

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study

British Journal of Clinical Pharmacology2020-07-165 citations

P540. Efficacy and safety of infliximab's biosimilar (REMSIMA) for IBD

Journal of Crohn s and Colitis2015-02-012 citations

P539. Outcome of acute severe ulcerative colitis in patients previously exposed to immunosoppressive therapy

Journal of Crohn s and Colitis2015-02-01

Long-term Pooled Safety Analysis of Once-Daily Multimatrix Mesalamine

The American Journal of Gastroenterology2014-10-011 citations